Back to Journals » Drug Design, Development and Therapy » Volume 2

Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin

Authors Yamamoto M, Takakura A, Masuda N

Published 28 September 2008 Volume 2008:2 Pages 189—192

DOI https://doi.org/10.2147/DDDT.S3972

Review by Single anonymous peer review

Peer reviewer comments 3


Michiko Yamamoto, Akira Takakura, Noriyuki Masuda

Department of Respiratory Medicine, Kitasato University School of Medicine, Kitasato, Japan

Abstract: Amrubicin is a totally synthetic anthracycline anticancer agent that acts as a potent topoisomerase II inhibitor. Amrubicin has been approved in Japan for the treatment of lung cancer, and the results from clinical studies of amrubicin as a single agent or as part of combination regimens for lung cancer, particularly for small cell lung cancer, conducted in Japan and overseas have been promising. Amrubicin should be included among new treatment strategies especially for chemoresistant patients. Here, preclinical, pharmacological, and clinical data on the use of amrubicin for the treatment of small cell lung cancer are reviewed.

Keywords: amrubicin, anthracycline, small-cell lung cancer, extensive disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]